New User:

-or-
Username:
Password:
Forgot your password?

Stock Market & Financial Investment News

News Breaks
April 25, 2014
08:18 EDTAZN, BCSAstraZeneca, Barclays investors push back on executive pay, Telegraph says
38.5% of AstraZeneca (AZN) shareholders voted against the company's executive pay plan, while 24% of investors voted against Barclays' (BCS) pay plan, reported The Telegraph. "We are disappointed with today's vote. As a priority we will be seeking to understand what concerns lay behind this," said an AstraZeneca spokesman. Reference Link
News For AZN;BCS From The Last 14 Days
Sign up for a free trial to see the rest of the stories you've been missing.
1 | 2 | all recent news | >>
October 21, 2014
07:15 EDTAZNFDA to hold workshop on breast cancer drug development
Subscribe for More Information
06:10 EDTAZNInovio, MedImmune, UPENN awarded $12.2M collaborative study by DARPA
Inovio Pharmaceuticals (INO) announced the Defense Advanced Research Projects Agency, or DARPA, has awarded $12.2M for a collaborative study that will be conducted by scientists from the Perelman School of Medicine at the University of Pennsylvania; Inovio Pharmaceuticals; and MedImmune, the global biologics research and development arm of AstraZeneca (AZN). The group will develop DNA-based monoclonal antibodies, or mAbs, for infectious disease treatment. DARPA is an agency of the US Department of Defense that creates and supports novel technologies important for national security. Together, the three organizations will develop and assess the DNA mAbs in preclinical studies using technology developed by Penn and licensed by Inovio. The collaboration will focus on three disease areas influenza virus, Pseudomonas aeruginosa and Staphylococcus aureus.
October 20, 2014
07:47 EDTAZNPfizer less likely to renew Astra pursuit after Shire deal breakdown, FT says
Subscribe for More Information
07:21 EDTBCSFederal Reserve Bank of New York and Boston to hold a workshop
Subscribe for More Information
07:19 EDTAZNIBC Life Sciences to hold a conference
Subscribe for More Information
07:14 EDTAZNEuropean College of Neuropsychopharmacology to hold a conference
27th ECNP Congress is being held in Berlin, Germany on October 18-21.
October 16, 2014
08:42 EDTBCSUBS, DOJ in talks for forex rigging settlement, FT reports
Subscribe for More Information
06:50 EDTBCSEuropean regulator rejects bonus loophole, NY Times says
Subscribe for More Information
October 15, 2014
10:48 EDTAZNShire tanks with AbbVie calling board meeting over merger
Subscribe for More Information
07:27 EDTBCSJPMorgan, HSBC fire traders linked to forex probe, WSJ reports
Subscribe for More Information
October 14, 2014
11:23 EDTAZNBIND Therapeutics and The Conference Forum hold a conference
Subscribe for More Information
06:45 EDTBCSData says UK banks paid less than 40% to cover mis-selling, Reuters says
Subscribe for More Information
October 13, 2014
10:08 EDTAZNOn The Fly: Analyst Upgrade Summary
Subscribe for More Information
09:21 EDTAZNOn The Fly: Pre-market Movers
Subscribe for More Information
07:53 EDTAZNAstraZeneca upgraded to Buy from Hold at Jefferies
Subscribe for More Information
05:27 EDTAZNAstraZeneca upgraded to Buy from Hold at Jefferies
Subscribe for More Information
October 10, 2014
09:13 EDTBCSEBA says EU stress test results to be published October 26
Subscribe for More Information
October 9, 2014
08:10 EDTAZNAstraZeneca reports Phase IIb study of benralizumab met primary endpoint
Subscribe for More Information
October 8, 2014
13:34 EDTBCSBarclays to pay $20M to settle accusations over Libor manipulation, Reuters say
Barclays has agreed to pay $20M to resolve a U.S. class action lawsuit over Libor manipulation, reports Reuters, citing court papers filed Wednesday. The $19.98M settlement must be approved by a federal judge. Reference Link
06:59 EDTBCSBarclays urges NY court to throw out fraud suit, Reuters says
Subscribe for More Information
1 | 2 | all recent news | >>

Sign up for a free trial to see the rest of the stories you've been missing.

I agree to the theflyonthewall.com disclaimer & terms of use